PubRank

Hiroji Uemura

Author PubWeight™ 61.68‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 2007 2.59
2 Ureteroscopy assisted retrograde nephrostomy: a new technique for percutaneous nephrolithotomy (PCNL). BJU Int 2011 2.14
3 The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level. Ann Nucl Med 2010 1.44
4 Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005 1.41
5 Stable suppression of tumorigenicity by Pin1-targeted RNA interference in prostate cancer. Clin Cancer Res 2005 1.35
6 Early ureteral catheter removal after ureteroscopic lithotripsy using ureteral access sheath. Urolithiasis 2012 1.25
7 Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging 2005 1.17
8 aPKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. Proc Natl Acad Sci U S A 2009 1.15
9 Gallbladder Metastasis from Renal Cell Carcinoma. Case Rep Oncol 2010 1.13
10 Identification of miR-30d as a novel prognostic maker of prostate cancer. Oncotarget 2012 1.11
11 Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxel. PLoS One 2012 1.06
12 Ureteroscopy-assisted retrograde nephrostomy (UARN) for an incomplete double ureter. Urol Res 2012 1.06
13 Alterations of p16 and p14ARF genes and their 9p21 locus in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009 1.01
14 Contrast-enhanced ultrasonography of the prostate: various imaging findings that indicate prostate cancer. BJU Int 2010 0.99
15 Preoperative stenting for ureteroscopic lithotripsy for a large renal stone. Int J Urol 2012 0.96
16 Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity. Int J Urol 2005 0.96
17 Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action. Prostate 2007 0.95
18 Reduction of prostate motion by removal of gas in rectum during radiotherapy. Int J Radiat Oncol Biol Phys 2008 0.94
19 Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients. Int J Clin Oncol 2005 0.94
20 Epithelioid angiomyolipoma of the kidney. Pathol Int 2009 0.92
21 Ureteral stent exchange under fluoroscopic guidance using the crochet hook technique in women. Urol Int 2012 0.92
22 Amplatz sheath for cystolithotripsy using Ho: YAG laser in female patients. Urology 2012 0.92
23 Effectiveness of ureteroscopy-assisted retrograde nephrostomy (UARN) for percutaneous nephrolithotomy (PCNL). PLoS One 2012 0.91
24 Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy. Int J Urol 2005 0.91
25 Analysis of NSAID-activated gene 1 expression in prostate cancer. Urol Int 2010 0.91
26 Ureteral stent retrieval using the crochet hook technique in females. PLoS One 2012 0.89
27 [Only metastasis to uterine corpus from superficial bladder cancer that of no original recurrence]. Hinyokika Kiyo 2007 0.88
28 Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. Prostate 2003 0.86
29 Stone area and volume are correlated with operative time for cystolithotripsy for bladder calculi using a holmium: yttrium garnet laser. Scand J Urol Nephrol 2012 0.85
30 The Neutrophil-to-Lymphocyte Ratio before Repeat Prostate Needle Biopsy for Predicting Prostate Cancer. Urol Int 2015 0.84
31 Magnetic nanoparticles of Fe3O4 enhance docetaxel-induced prostate cancer cell death. Int J Nanomedicine 2013 0.84
32 Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer. Prostate 2012 0.84
33 Choosing an appropriate length of loop type ureteral stent using direct ureteral length measurement. Urol Int 2011 0.84
34 Regulation of androgen receptor expression through angiotensin II type 1 receptor in prostate cancer cells. Prostate 2010 0.84
35 Complete response, as determined by prostate-specific antigen level, to chlormadinone acetate withdrawal persisting longer than 2 years in patients with advanced prostate cancer: two case reports. Int J Urol 2006 0.84
36 [A case of upper urinary tract metastases from sigmoid colon cancer]. Hinyokika Kiyo 2009 0.83
37 High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients. BMC Cancer 2014 0.83
38 55 kDa nuclear matrix protein (nmt55) mRNA is expressed in human prostate cancer tissue and is associated with the androgen receptor. Int J Cancer 2003 0.82
39 Changing to a loop-type ureteral stent decreases patients' stent-related symptoms. Urol Res 2012 0.81
40 High-grade invasive urothelial carcinoma with focal plasmacytoid differentiation successfully treated by transurethral resection followed by chemoradiotherapy. Int J Urol 2011 0.81
41 Evaluation of role of angiotensin III and aminopeptidases in prostate cancer cells. Prostate 2008 0.80
42 Coexpression of aPKCλ/ι and IL-6 in prostate cancer tissue correlates with biochemical recurrence. Cancer Sci 2011 0.80
43 Clinical evaluation of choline measurement by proton MR spectroscopy in patients with malignant tumors. Radiat Med 2004 0.79
44 Identification of phosphorylated proteins involved in the oncogenesis of prostate cancer via Pin1-proteomic analysis. Prostate 2011 0.79
45 Spontaneous renal hemorrhage in hemodialysis patients. Case Rep Nephrol Urol 2011 0.79
46 Which is the best method to estimate the actual ureteral length in patients undergoing ureteral stent placement? Int J Urol 2012 0.79
47 Combination treatment with 1alpha,25-dihydroxyvitamin D3 and 9-cis-retinoic acid directly inhibits human telomerase reverse transcriptase transcription in prostate cancer cells. Mol Cancer Ther 2003 0.79
48 [Multi-center trial on the early effects of silodosin on lower urinary tract symptoms associated with benign prostatic hyperplasia]. Hinyokika Kiyo 2008 0.78
49 [A case of salvage combination chemotherapy of gemcitabine plus nedaplatin for squamous cell carcinoma of the ureter]. Hinyokika Kiyo 2006 0.78
50 Angiotensin receptor blockers and risk of prostate cancer among United States veterans. J Clin Pharmacol 2013 0.78
51 An immunohistochemical scoring system of prolyl isomerase Pin1 for predicting relapse of prostate carcinoma after radical prostatectomy. Pathol Res Pract 2006 0.78
52 Angiotensin II blocker decreases serum prostate specific antigen in hormone refractory prostate cancer. J Urol 2005 0.78
53 Antitumour effect of electrochemotherapy with bleomycin on human prostate cancer xenograft. BJU Int 2008 0.77
54 Liprin-alpha2 gene, protein tyrosine phosphatase LAR interacting protein related gene, is downregulated by androgens in the human prostate cancer cell line LNCaP. Int J Mol Med 2002 0.77
55 Ureteroscopy-assisted retrograde nephrostomy for lower calyx calculi in horseshoe kidney: two case reports. J Med Case Rep 2012 0.77
56 Free PSA/total PSA ratio increases the detection rate of prostate cancer in twelve-core biopsy. Urol Int 2009 0.77
57 [Usefulness of extension of disease as a prognostic factor in relapsed prostate cancer patients of stage D]. Nihon Hinyokika Gakkai Zasshi 2005 0.77
58 Neuroserpin (PI-12) is upregulated in high-grade prostate cancer and is associated with survival. Int J Cancer 2005 0.76
59 Ureteroscopy-assisted retrograde nephrostomy for percutaneous nephrolithotomy after urinary diversion. Case Rep Nephrol Urol 2012 0.75
60 Neuroendocrine Carcinoma of the Bladder. Case Rep Oncol 2010 0.75
61 Inhibition of growth of human prostate cancer xenograft by transfection of p53 gene: gene transfer by electroporation. Mol Cancer Ther 2002 0.75
62 Ureteroscopy-Assisted Retrograde Nephrostomy (UARN) after Anatrophic Nephrolithotomy. Case Rep Med 2012 0.75
63 Encrusted Ureteral Stent Retrieval Using Flexible Ureteroscopy with a Ho: YAG Laser. Case Rep Med 2012 0.75
64 Ramelteon combined with an α1-blocker decreases nocturia in men with benign prostatic hyperplasia. BMC Urol 2013 0.75
65 Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer. Cancer Sci 2014 0.75
66 Primary Synovial Sarcoma of the Kidney. Case Rep Oncol 2009 0.75
67 Authors' response to Chew and Lange. J Endourol 2013 0.75
68 Correlation between the operation time using two different power settings of a Ho: YAG laser: laser power doesn't influence lithotripsy time. BMC Res Notes 2013 0.75
69 [High-dose chemotherapy with peripheral blood stem cell transplantation for advanced testicular cancer]. Hinyokika Kiyo 2002 0.75
70 Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer. Urol Int 2017 0.75
71 Transurethral bladder tumor resection (TUR-Bt) in a patient with Osler-Rendu-Weber syndrome. Urology 2010 0.75
72 [Mixed epithelial and stromal tumor of kidney: a case report]. Hinyokika Kiyo 2009 0.75
73 [A case of adult-onset idiopathic hypogonadotropic hypogonadism presenting with infertility]. Hinyokika Kiyo 2009 0.75
74 [Case of sarcomatoid renal cell carcinoma developed in the chalked kidney (putty kidney)]. Hinyokika Kiyo 2009 0.75
75 [Abiraterone (CYP17 inhibitor)]. Nihon Rinsho 2016 0.75
76 [A case of laparoscopic heminephroureterectomy for ureter cancer in a horseshoe kidney]. Nihon Hinyokika Gakkai Zasshi 2007 0.75
77 Double ureteral access sheath (UAS) technique for complicated distal ureteral stone. Urolithiasis 2014 0.75
78 The 7th American Urological Association and the Japanese Urological Association international affiliate society meeting. Int J Urol 2012 0.75
79 Recovery of serum prostate specific antigen value after interruption of antiandrogen therapy with allylestrenol for benign prostatic hyperplasia. Hinyokika Kiyo 2006 0.75
80 [Two cases of testicular tumors with high alpha-fetoprotein levels: a case report]. Hinyokika Kiyo 2005 0.75
81 [Laparoscopic right partial nephrectomy in the presence of Riedel's lobe of the liver]. Hinyokika Kiyo 2009 0.75
82 [Treatment of androgen-independent hormone refractory prostate cancer using docetaxel]. Nihon Rinsho 2005 0.75
83 [Questionnaire on suitableness and acceptableness of cancer notification in aged Japanese prostate cancer patients]. Nihon Hinyokika Gakkai Zasshi 2006 0.75
84 [Investigation of 14 renal cell carcinoma cases with tumor thrombus in the inferior vena cava]. Hinyokika Kiyo 2003 0.75
85 [Propiverine hydrochloride improved correlatively subjective QOL and objective findings in Japanese patients with urinary frequency and/or incontinence]. Hinyokika Kiyo 2006 0.75
86 Role of renin-angiotensin system (RAS) in cancer. Curr Cancer Drug Targets 2011 0.75
87 [Renin-angiotensin system (RAS) as new molecular therapeutic targets in prostate cancer]. Nihon Rinsho 2012 0.75
88 [Chemotherapy with low-dose docetaxel and estramustine phosphate in patient with liver dysfunction due to liver metastases of hormone-refractory prostate cancer : a case report]. Hinyokika Kiyo 2010 0.75
89 [A case of primary choriocarcinoma of the bladder]. Hinyokika Kiyo 2004 0.75
90 [Role of chemotherapy in the treatment of castration resistant prostate cancer]. Nihon Rinsho 2016 0.75
91 [New generation of androgen receptor antagonist in castration resistant prostate cancer]. Nihon Rinsho 2014 0.75